Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.13 CAD
Change Today +0.015 / 13.64%
Volume 31.9K
As of 4:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

diagnocure inc (CUR) Snapshot

Open
C$0.14
Previous Close
C$0.11
Day High
C$0.14
Day Low
C$0.11
52 Week High
06/18/14 - C$0.20
52 Week Low
12/22/14 - C$0.09
Market Cap
5.4M
Average Volume 10 Days
27.1K
EPS TTM
C$-0.04
Shares Outstanding
43.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAGNOCURE INC (CUR)

Related News

No related news articles were found.

diagnocure inc (CUR) Related Businessweek News

No Related Businessweek News Found

diagnocure inc (CUR) Details

DiagnoCure Inc., a life sciences company, develops and commercializes cancer diagnostic tests for the detection and management of cancer. The company primarily focuses on molecular diagnostic tests. It offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for use in colorectal cancer management. The company also provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environment services. DiagnoCure Inc. was founded in 1994 and is headquartered in Quebec, Canada.

10 Employees
Last Reported Date: 01/27/15
Founded in 1994

diagnocure inc (CUR) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: C$180.1K
Interim Chief Financial Officer and Senior Di...
Total Annual Compensation: C$129.7K
Compensation as of Fiscal Year 2013.

diagnocure inc (CUR) Key Developments

DiagnoCure Inc. - Shareholder/Analyst Call

To review the scientific progress; to review of business development initiatives; to review financial summary; and to discuss highlights and corporate focus

DiagnoCure, Inc. Reports Consolidated Financial Results for the First Quarter Ended January 31, 2015

DiagnoCure Inc. reported consolidated financial results for the first quarter ended January 31, 2015. Total revenues for the first quarter of 2015 were $142,915 compared with $146,969 for the same period of 2014. Without taking into account the effect of the exchange rate variation, total revenues decreased by 15%, to $112,381 for the first quarter of 2015 compared with $132,178 for the same period of 2014. This decrease is mainly attributable to a decrease of 32% in PCA3 European royalty revenues as compared to the same period in 2014. Net loss (before stock-based compensation, depreciation and amortization) was $243,291 against $427,273 a year ago. Basic and diluted net loss per share was $0.01 against $0.01 a year ago.

DiagnoCure Inc., Annual General Meeting, Apr 30, 2015

DiagnoCure Inc., Annual General Meeting, Apr 30, 2015., at 13:30 US Eastern Standard Time. Location: McCarthy Tétrault's offices. Agenda: To consider the consolidated financial statements for the year ended October 31, 2014, accompanied by the report of the auditor; to elect directors; to appoint the auditor and to authorize the directors to determine the remuneration of the auditor; and to transact such other business as may properly be brought before the Meeting or any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUR:CN C$0.13 CAD +0.015

CUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CUR.
View Industry Companies
 

Industry Analysis

CUR

Industry Average

Valuation CUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAGNOCURE INC, please visit www.diagnocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.